    |
 |
|
|
||||
|
|||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Sample PIPE Candidate Report |
Download an Excel version of this report
|
Sector Preference: |
Consumer-
Non-Cyclical (Healthcare) |
|
Display Options: |
Display only the
first 10 Companies |
|
Burn Rate Range: |
$0.00 or smaller |
|
Quarters of Cash Left Range: |
Between 7 and 8 |
Glossary of Terms and Formulas
| Company Name | Company Symbol | Sector | Industry | Primary Exchange | Quarters of Cash Remaining | Current Cash & Mktable Secs | Cash Flow Rate/Burn Rate (if neg.) | Period End Date | Last Placement Date | Last Placement Security Sold | Last Placement Gross Proceeds | Last Placement Agent Fees | Last Placement Agent | Last Placement Lead Investor | Current Outstanding Shares | Current Market Price | Volume (3 Month Avg) | Dollar Volume | Current Market Cap | Estimated Future PIPE Size | Days Required to Resell Est. PIPE | Quarters of Cash Generated by Est. PIPE | Shelf Filing Date |
| ACUSPHERE INC | ACUS | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.95793 | $79,766,676 | - $10,023,551 | 03/31/05 | 07/29/2004 | Common Stock | $21,491,419 | $1,739,350 | SG Cowen & Co., LLC | Quaker Capital Partners I, L.P. | 17,832,000 | 6.200 | 54,695 | $339,106 | $110,558,400 | $11,055,840 | 326 | 1.1030 | 04/05/05 |
| ALKERMES INC | ALKS | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.16842 | $202,567,000 | - $28,258,250 | 03/31/05 | 08/22/2003 | Convertible Subordinated Notes | $125,000,000 | $3,900,000 | U.S. Bancorp Piper Jaffray, Inc. | Highbridge International LLC | 90,405,000 | 16.060 | 1,036,045 | $16,638,783 | $1,451,895,260 | $145,189,526 | 87 | 5.1380 | |
| ANGIOTECH PHARMACEUTICALS INC | ANPI | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.06392 | $271,484,000 | - $38,432,500 | 12/31/04 | 84,113,000 | 13.370 | 553,596 | $7,401,577 | $1,124,590,810 | $112,459,081 | 152 | 2.9261 | |||||||
| AVANT IMMUNOTHERAPEUTICS INC | AVAN | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.79809 | $27,309,120 | - $3,502,027 | 03/31/05 | 02/13/2004 | Common Stock - Shelf Sale (Registered Direct) | $24,653,750 | $1,479,225 | Roth Capital Partners, LLC | Unnamed Institutional Investors (Various) | 74,133,000 | 1.320 | 377,843 | $498,752 | $97,855,560 | $9,785,556 | 196 | 2.7943 | 10/09/03 |
| AXCAN PHARMA INC | AXCA | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.83848 | $37,901,000 | - $4,835,250 | 09/30/04 | 03/05/2003 | Convertible Subordinated Notes | $125,000,000 | $3,750,000 | J.P. Morgan Chase & Co. | Unnamed Institutional Investors (Various) | 45,618,000 | 15.150 | 203,220 | $3,078,789 | $691,112,700 | $69,111,270 | 224 | 14.2932 | |
| BIOMIRA INC | BIOM | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.61227 | $32,081,131 | - $4,214,395 | 12/31/04 | 12/08/2004 | Common Stock - Shelf Sale (Registered Direct) | $12,570,001 | $502,800 | Rodman & Renshaw, LLC | Unnamed Institutional Investors (Various) | 78,817,000 | 1.600 | 399,639 | $639,422 | $126,107,200 | $12,610,720 | 197 | 2.9923 | |
| COMMONWEALTH BIOTECHNOLOGIES INC | CBTE | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq Smallcap Mkt | 7.74706 | $2,774,552 | - $358,143 | 03/31/05 | 05/27/2004 | Common Stock | $2,500,000 | $264,048 | Jesup & Lamont Securities Corporation | DSAM Fund LP | 3,204,000 | 5.160 | 15,081 | $77,820 | $16,532,640 | $1,653,264 | 212 | 4.6162 | |
| CRYOLIFE INC | CRY | Consumer/Non-Cyclical (Healthcare) | Medical Equipment & Supplies | NYSE | 7.81281 | $26,128,000 | - $3,344,250 | 03/31/05 | 01/26/2004 | Common Stock | $21,525,000 | $1,525,000 | Piper Jaffray & Co. | Smithfield Fiduciary, LLC | 23,714,000 | 7.670 | 100,828 | $773,352 | $181,886,380 | $18,188,638 | 235 | 5.4388 | 12/17/04 |
| CURIS INC | CRIS | Consumer/Non-Cyclical (Healthcare) | Biotechnology & Drugs | Nasdaq National Mkt | 7.32327 | $45,895,652 | - $6,267,095 | 03/31/05 | 10/12/2004 | Common Stock - Shelf Sale (Registered Direct) | $20,098,972 | $1,198,972 | Leerink Swann & Co. | Unnamed Institutional Investors (Various) | 47,901,000 | 4.790 | 218,465 | $1,046,446 | $229,445,790 | $22,944,579 | 219 | 3.6611 | 12/23/03 |
| ENDOLOGIX INC /DE/ | ELGX | Consumer/Non-Cyclical (Healthcare) | Medical Equipment & Supplies | Nasdaq National Mkt | 7.42349 | $16,057,000 | - $2,163,000 | 03/31/05 | 07/05/2005 | Common Stock | $16,600,000 | $1,100,000 | Adams Harkness, Inc. | Goldman Sachs & Co. | 31,918,000 | 5.820 | 91,692 | $533,648 | $185,762,760 | $18,576,276 | 348 | 8.5882 |
| Questions? Email Customer Support | Privacy Policy Important Legal Disclosure |
 |
|
